Published in Circ Shock on November 01, 1994
The pathogenesis of sepsis. Annu Rev Pathol (2011) 2.55
Tissue factor-dependent coagulation is preferentially up-regulated within arterial branching areas in a baboon model of Escherichia coli sepsis. Am J Pathol (2005) 1.37
Dysregulation of coagulation in cerebral malaria. Mol Biochem Parasitol (2009) 1.29
Tissue factor as an initiator of coagulation and inflammation in the lung. Crit Care (2008) 1.22
Bench-to-bedside review: endothelial cell dysfunction in severe sepsis: a role in organ dysfunction? Crit Care (2003) 1.18
Tissue factor and thrombosis: The clot starts here. Thromb Haemost (2010) 1.16
Scientific and clinical challenges in sepsis. Curr Pharm Des (2009) 1.14
Tissue factor as a proinflammatory agent. Arthritis Res (2002) 1.04
Intra-alveolar tissue factor pathway inhibitor is not sufficient to block tissue factor procoagulant activity. Am J Physiol Lung Cell Mol Physiol (2008) 1.00
Role of tissue factor in thrombosis in antiphospholipid antibody syndrome. Lupus (2010) 0.86
The Interface between Inflammation and Coagulation in Cardiovascular Disease. Int J Inflam (2012) 0.84
Interdependent biological systems, multi-functional molecules: the evolving role of tissue factor pathway inhibitor beyond anti-coagulation. Thromb Res (2010) 0.78
Tissue factor pathway inhibitor is an inhibitor of factor VII-activating protease. J Thromb Haemost (2012) 0.77
Myeloid tissue factor does not modulate lung inflammation or permeability during experimental acute lung injury. Sci Rep (2016) 0.77
Endogenous tissue factor pathway inhibitor has a limited effect on host defence in murine pneumococcal pneumonia. Thromb Haemost (2015) 0.75
Feasibility and Safety of Local Treatment with Recombinant Human Tissue Factor Pathway Inhibitor in a Rat Model of Streptococcus pneumoniae Pneumonia. PLoS One (2015) 0.75
Construction and characterization of amplifiable multicopy DNA cloning vehicles derived from the P15A cryptic miniplasmid. J Bacteriol (1978) 75.38
Nonchromosomal antibiotic resistance in bacteria: genetic transformation of Escherichia coli by R-factor DNA. Proc Natl Acad Sci U S A (1972) 57.06
Construction of biologically functional bacterial plasmids in vitro. Proc Natl Acad Sci U S A (1973) 25.61
Recircularization and autonomous replication of a sheared R-factor DNA segment in Escherichia coli transformants. Proc Natl Acad Sci U S A (1973) 13.45
Replication and transcription of eukaryotic DNA in Escherichia coli. Proc Natl Acad Sci U S A (1974) 10.51
Phenotypic expression in E. coli of a DNA sequence coding for mouse dihydrofolate reductase. Nature (1978) 8.76
Decay of mRNA in Escherichia coli: investigation of the fate of specific segments of transcripts. Proc Natl Acad Sci U S A (1983) 6.79
Nucleotide sequence of cloned cDNA for bovine corticotropin-beta-lipotropin precursor. Nature (1979) 6.56
Molecular cloning of the complementary DNA for human tumor necrosis factor. Science (1985) 6.18
Revised interpretation of the origin of the pSC101 plasmid. J Bacteriol (1977) 5.51
Genome construction between bacterial species in vitro: replication and expression of Staphylococcus plasmid genes in Escherichia coli. Proc Natl Acad Sci U S A (1974) 5.47
Structure and genomic organization of the mouse dihydrofolate reductase gene. Cell (1980) 4.25
Indirect selection of bacterial plasmids lacking identifiable phenotypic properties. J Bacteriol (1975) 3.88
Postoperative course and hemodynamic profile after the arterial switch operation in neonates and infants. A comparison of low-flow cardiopulmonary bypass and circulatory arrest. Circulation (1995) 3.80
Cloning and analysis of strong promoters is made possible by the downstream placement of a RNA termination signal. Proc Natl Acad Sci U S A (1981) 3.77
Isolation of histone genes from unfractionated sea urchin DNA by subculture cloning in E. coli. Nature (1975) 3.70
Studies of mouse mitochondrial DNA in Escherichia coli: structure and function of the eucaryotic-procaryotic chimeric plasmids. Cell (1975) 2.80
Outcome and assessment after the modified Fontan procedure for hypoplastic left heart syndrome. Circulation (1992) 2.15
Characterization of the structural gene and putative 5'-regulatory sequences for human proopiomelanocortin. Nature (1982) 2.04
Impact of encephalopathy on mortality in the sepsis syndrome. The Veterans Administration Systemic Sepsis Cooperative Study Group. Crit Care Med (1990) 2.04
Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest (1993) 2.00
A proenzyme form of human urokinase. J Biol Chem (1982) 1.98
A macrophage protein, Ym1, transiently expressed during inflammation is a novel mammalian lectin. J Biol Chem (2001) 1.88
Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J (1990) 1.87
Alterations in p53 and p16INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts. Mol Cell Biol (1995) 1.85
Incidental vesicoureteral reflux in neonates with antenatally detected hydronephrosis and other renal abnormalities. Radiology (1993) 1.83
Video-assisted thoracoscopic division of a vascular ring in an infant: a new operative technique. J Card Surg (1993) 1.82
The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood (2000) 1.80
cDNA cloning and expression in Escherichia coli of a plasminogen activator inhibitor from human placenta. J Biol Chem (1987) 1.79
Comparison of gastrin and histamine on gastric mucosal blood flow. Proc Soc Exp Biol Med (1969) 1.73
Outcome of cardiopulmonary resuscitation in a pediatric cardiac intensive care unit. Crit Care Med (2000) 1.71
Impact of respiratory syncytial virus infection on surgery for congenital heart disease: postoperative course and outcome. Crit Care Med (1999) 1.66
Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings. Circulation (1992) 1.63
Two-stage response to endotoxin infusion into normal human subjects: Correlation of blood phagocyte luminescence with clinical and laboratory markers of the inflammatory, hemostatic response. Crit Care Med (2001) 1.61
A method for selective cloning of eukaryotic DNA fragments in Escherichia coli by repeated transformation. Mol Gen Genet (1974) 1.61
The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsis. Crit Care Med (2001) 1.57
One-stage repair of interrupted aortic arch, ventricular septal defect, and subaortic obstruction in the neonate: a novel approach. J Thorac Cardiovasc Surg (1996) 1.55
A high molecular weight component of the human tumor necrosis factor receptor is associated with cytotoxicity. Proc Natl Acad Sci U S A (1987) 1.54
Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. J Biol Chem (1990) 1.52
Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood (2001) 1.51
Initiation of protein synthesis in bacteria at a translational start codon of mamalian cDNA: effects of the preceding nucleotide sequence. Proc Natl Acad Sci U S A (1980) 1.51
Genetic expression in bacteriophage lambda. 3. Inhibition of Escherichia coli nucleic acid and protein synthesis during lambda development. J Mol Biol (1970) 1.50
Emergent stent placement for acute Blalock-Taussig shunt obstruction after stage 1 Norwood surgery. Cathet Cardiovasc Diagn (1997) 1.50
Macromolecular enzymatic product of NAD+ in liver mitochondria. Proc Natl Acad Sci U S A (1975) 1.48
Isolation and characterization of urokinase from human plasma. J Biol Chem (1982) 1.47
Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor. Circulation (1991) 1.47
Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene (2006) 1.47
Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa. Blood (1992) 1.46
Structural organization of human genomic DNA encoding the pro-opiomelanocortin peptide. Proc Natl Acad Sci U S A (1980) 1.44
Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med (2001) 1.41
Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha). Circ Shock (1990) 1.39
DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage. Blood (1991) 1.36
Site-directed mutagenesis of a conserved region of the 5-enolpyruvylshikimate-3-phosphate synthase active site. J Biol Chem (1991) 1.36
Effects of acetylsalicylic acid on the canine response to endotoxin. J Pharmacol Exp Ther (1967) 1.33
Site-specific mutagenesis of the human fibroblast interferon gene. Proc Natl Acad Sci U S A (1984) 1.32
Genetic organization and functional analysis of the otn DNA essential for cell-wall polysaccharide synthesis in Vibrio cholerae O139. Mol Microbiol (1996) 1.30
Interferon increases HLA synthesis in melanoma cells: interferon-resistant and -sensitive cell lines. Proc Natl Acad Sci U S A (1982) 1.29
Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. J Biol Chem (1992) 1.29
Matrix metalloproteinases cleave tissue factor pathway inhibitor. Effects on coagulation. J Biol Chem (2000) 1.29
The organization of sea urchin histone genes. Cell (1975) 1.28
Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1. Am J Pathol (1999) 1.27
Characteristics of tumor cell bioactivity in oncogenic osteomalacia. Mol Cell Endocrinol (1996) 1.25
gas7: A gene expressed preferentially in growth-arrested fibroblasts and terminally differentiated Purkinje neurons affects neurite formation. Proc Natl Acad Sci U S A (1998) 1.25
Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem (1993) 1.23
The crystal structure of a novel mammalian lectin, Ym1, suggests a saccharide binding site. J Biol Chem (2001) 1.23
Covalent modification of proteins by metabolites of NAD+. Proc Natl Acad Sci U S A (1976) 1.23
The effect of leukocyte elastase on tissue factor pathway inhibitor. Blood (1992) 1.22
Role of G0-G1 arrest in the inhibition of tumor cell growth by interferon. Proc Natl Acad Sci U S A (1980) 1.20
Plasminogen activator inhibitor types 1 and 2 in human trophoblasts. PAI-1 is an immunocytochemical marker of invading trophoblasts. Lab Invest (1989) 1.19
Three-dimensional structure of human cytomegalovirus protease. Nature (1996) 1.18
Constitutive activation of integrin alpha 4 beta 1 defines a unique stage of human thymocyte development. J Exp Med (1994) 1.18
Biological properties of human melanoma cells in culture. In Vitro (1979) 1.18
Biological effects of recombinant human tumor necrosis factor and its novel muteins on tumor and normal cell lines. Cancer Res (1987) 1.17
Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood (1991) 1.17
Cardiorespiratory and metabolic responses to liver E. coli and endotoxin in the monkey. J Appl Physiol (1969) 1.16
Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood (2000) 1.15
Effects of endotoxin on pulmonary capillary permeability, ultrastructure, and surfactant. Surg Gynecol Obstet (1969) 1.14
Cures and partial regression of murine and human tumors by recombinant human tumor necrosis factor. Cancer Res (1986) 1.13
Mesenteric vascular responses to endotoxin in the monkey and dog. Am J Physiol (1970) 1.12
The pulmonary ultrastructure in septic shock. Exp Mol Pathol (1970) 1.12
Stanniocalcin 1 and 2 are secreted as phosphoproteins from human fibrosarcoma cells. Biochem J (2000) 1.10
Nitrification and denitrification processes related to waste water treatment. Adv Appl Microbiol (1975) 1.10
Effect of indomethacin in endotoxin shock in the dog. Proc Soc Exp Biol Med (1967) 1.09
A model for thrombin protection against endotoxin. Thromb Res (1984) 1.09
Large-scale recovery and purification of L-asparaginase from Erwinia carotovora. Appl Biochem Biotechnol (1986) 1.08
Rapid cardiopulmonary support for children with complex congenital heart disease. Ann Thorac Surg (2000) 1.08
Mammalian protein secretion without signal peptide removal. Biosynthesis of plasminogen activator inhibitor-2 in U-937 cells. J Biol Chem (1988) 1.08
Effectiveness of steroid/antibiotic treatment in primates administered LD100 Escherichia coli. Ann Surg (1981) 1.08
Biosynthesis of a prostaglandin by a plant enzyme. J Biol Chem (1978) 1.07
Survival of primates in LD100 septic shock following steroid/antibiotic therapy. J Surg Res (1980) 1.07
Continuous arteriovenous hemofiltration therapy for Staphylococcus aureus-induced septicemia in immature swine. Crit Care Med (1993) 1.05
Identification of determinants involved in binding of tissue-type plasminogen activator-plasminogen activator inhibitor type 1 complexes to HepG2 cells. J Biol Chem (1990) 1.05
Detection of the 'hyperdynamic state' of sepsis in the baboon during lethal E. coli infusion. J Trauma (1983) 1.04